



03CO  
09/6/01 #5

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (6-98)  
Approved for use through 09/30/2000. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/896,692
	Filing Date	June 29, 2001
	First Named Inventor	Agrawal
	Group Art Unit	
	Examiner Name	
Total Number of Pages in This Submission	5	Attorney Docket Number (HYZ-069CN) 47508.556

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Additional Enclosure(s) (please identify below)
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	PTO Form 1449 with references	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Ann-Louise Kerner, Ph.D. (Reg. No. 33,523)
Signature	<i>Ann-Louise Kerner</i>
Date	September 5, 2001

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: 9/5/01			
Typed or printed name	MELANIE LEGARE		
Signature	<i>Melanie Legare</i>	Date	September 5, 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



**PATENT**

Attorney Docket No.: HYZ-069CN (47508.556)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Sudhir Agrawal

Serial No.: 09/896,692

Examiner: Not Yet Assigned

Filed: June 29, 2001

Group Art Unit:

For: NOVEL HIV-SPECIFIC OLIGONUCLEOTIDES AND METHODS OF THEIR USE

Assistant Commissioner for Patents  
Washington, D.C. 20231

**CERTIFICATE UNDER 37 C.F.R. 1.8(a)**

I hereby certify that this correspondence is being as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

Sept. 5, 2001  
Date

Melanie Legare  
Melanie Legare

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Applicant and their attorney are aware of the following publications and information listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. Please note, however, that reference **A11**, *Remington's Pharmaceuticals Sciences* (18<sup>th</sup> Ed.) is not enclosed as it is a book and too voluminous to provide with this Statement.

This submission does not represent that a search has been made and does not constitute an admission that the listed documents are material to patentability or that the listed documents are prior art. If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.


U.S.S.N. 09/896,692  
Agrawal  
Page 2

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits and is therefore submitted as both timely and proper; therefore, no fees are believed to be due.

The Commissioner, however, is hereby authorized to charge any fee deficiency or credit any overpayment to Deposit Account No. 08-0219.

Date: Sept. 5, 2001

Respectfully submitted,



Ann-Louise Kerner, Ph.D.  
Registration No. 33,523  
Attorney for Applicant

Hale and Dorr LLP  
60 State Street  
Boston, Massachusetts 02109  
Tel: (617) 526-6192  
Fax: (617) 526-5000